Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Alpha Tau Medical Ltd ( (DRTS) ) is now available.
On September 2, 2025, Alpha Tau Medical Ltd. announced the successful treatment of the first patient in its U.S. multi-center pancreatic cancer clinical trial, known as the IMPACT study. This pilot study explores the combination of Alpha DaRT with chemotherapy for patients with newly diagnosed unresectable locally advanced or metastatic pancreatic adenocarcinoma. With pancreatic cancer being the third leading cause of cancer-related death in the U.S., the study aims to address the high unmet needs of patients who are often deemed inoperable at diagnosis. The trial’s initiation marks a significant step in Alpha Tau’s strategy to provide innovative treatment options for challenging cancers, potentially improving local control and overall outcomes for patients.
The most recent analyst rating on (DRTS) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on Alpha Tau Medical Ltd stock, see the DRTS Stock Forecast page.
Spark’s Take on DRTS Stock
According to Spark, TipRanks’ AI Analyst, DRTS is a Underperform.
Alpha Tau Medical Ltd is struggling with significant financial challenges, primarily due to a lack of revenue and ongoing cash burn. While technical indicators show a neutral trend, the valuation metrics reflect the company’s unprofitability. The absence of earnings call insights and corporate events limits additional context. Overall, the stock is risky with a low score of 38, suggesting caution for potential investors.
To see Spark’s full report on DRTS stock, click here.
More about Alpha Tau Medical Ltd
Alpha Tau Medical Ltd., founded in 2016, is an Israeli oncology therapeutics company focused on the research, development, and potential commercialization of its Alpha DaRT technology for treating solid tumors. The technology, developed by Professors Itzhak Kelson and Yona Keisari from Tel Aviv University, aims to deliver highly potent and conformal alpha-irradiation to solid tumors.
Average Trading Volume: 49,355
Technical Sentiment Signal: Buy
Current Market Cap: $289.7M
For a thorough assessment of DRTS stock, go to TipRanks’ Stock Analysis page.